Literature DB >> 23508806

Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Lisa Gherardini1, Giuseppe Bardi, Mariangela Gennaro, Tommaso Pizzorusso.   

Abstract

RNA interference has been envisaged as a powerful tool for molecular and clinical investigation with a great potential for clinical applications. In recent years, increased understanding of cancer biology and stem cell biology has dramatically accelerated the development of technology for cell and gene therapy in these areas. This paper is a review of the most recent report of innovative use of siRNA to benefit several central nervous system diseases. Furthermore, a description is made of innovative strategies of delivery into the brain by means of viral and non-viral vectors with high potential for translation into clinical use. Problems are also highlighted that might hamper the transition from bench to bed, analyzing the lack of reliable preclinical models with predictive validity and the lack of effective delivery systems, which are able to overcome biological barriers and specifically reach the brain site of action.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23508806     DOI: 10.1007/s00018-013-1310-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  195 in total

1.  Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease.

Authors:  Ryan L Boudreau; Ryan M Spengler; Beverly L Davidson
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.

Authors:  Jonathan Low; Wayne Blosser; Michele Dowless; Lucia Ricci-Vitiani; Roberto Pallini; Ruggero de Maria; Louis Stancato
Journal:  J Biomol Screen       Date:  2011-09-28

Review 3.  RNAi medicine for the brain: progresses and challenges.

Authors:  Ryan L Boudreau; Edgardo Rodríguez-Lebrón; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

4.  Glioma growth inhibition in vitro and in vivo by single chain variable fragments of the transferrin receptor conjugated to survivin small interfering RNA.

Authors:  F Wang; H-R Bai; J Wang; Y-Z Bai; C-W Dou
Journal:  J Int Med Res       Date:  2011       Impact factor: 1.671

5.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

6.  Evidence that gamma-secretase-mediated Notch signaling induces neuronal cell death via the nuclear factor-kappaB-Bcl-2-interacting mediator of cell death pathway in ischemic stroke.

Authors:  Thiruma V Arumugam; Yi-Lin Cheng; Yuri Choi; Yun-Hyung Choi; Sunghee Yang; Young-Kwang Yun; Jong-Sung Park; Dong Kwon Yang; John Thundyil; Mathias Gelderblom; Vardan T Karamyan; Sung-Chun Tang; Sic L Chan; Tim Magnus; Christopher G Sobey; Dong-Gyu Jo
Journal:  Mol Pharmacol       Date:  2011-03-30       Impact factor: 4.436

Review 7.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

8.  Delivery of cationic polymer-siRNA nanoparticles for gene therapies in neural regeneration.

Authors:  Yanran Liang; Zhonglin Liu; Xintao Shuai; Weiwei Wang; Jun Liu; Wei Bi; Chuanming Wang; Xiuna Jing; Yunyun Liu; Enxiang Tao
Journal:  Biochem Biophys Res Commun       Date:  2012-04-21       Impact factor: 3.575

9.  siRNA-mediated gene silencing in vitro and in vivo.

Authors:  Haibin Xia; Qinwen Mao; Henry L Paulson; Beverly L Davidson
Journal:  Nat Biotechnol       Date:  2002-09-16       Impact factor: 54.908

10.  c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro.

Authors:  Sheng-Hua Chu; Dong-Fu Feng; Hong Zhang; Er-Tao Chen; Zhi-Xin Duan; Xue-Yuan Li; Jia Li; Yan-Bin Ma; Zhi-An Zhu; Jian-Hua Qiu
Journal:  J Neurooncol       Date:  2009-01-24       Impact factor: 4.130

View more
  7 in total

Review 1.  Beyond traditional pharmacology: new tools and approaches.

Authors:  E V Gurevich; V V Gurevich
Journal:  Br J Pharmacol       Date:  2015-06-10       Impact factor: 8.739

2.  Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.

Authors:  Marta Pardo; Yuyan Cheng; Dmitry Velmeshev; Marco Magistri; Hagit Eldar-Finkelman; Ana Martinez; Mohammad A Faghihi; Richard S Jope; Eleonore Beurel
Journal:  JCI Insight       Date:  2017-03-23

Review 3.  RNA delivery biomaterials for the treatment of genetic and rare diseases.

Authors:  Weiyu Zhao; Xucheng Hou; Olivia G Vick; Yizhou Dong
Journal:  Biomaterials       Date:  2019-06-20       Impact factor: 12.479

4.  Non-viral Vector Mediated RNA Interference Technology for Central Nerve System Injury.

Authors:  Christian Macks; Jeoung Soo Lee
Journal:  DNA RNA Nanotechnol       Date:  2016-08-25

5.  Local delivery of RhoA siRNA by PgP nanocarrier reduces inflammatory response and improves neuronal cell survival in a rat TBI model.

Authors:  Christian Macks; DaUn Jeong; Jeoung Soo Lee
Journal:  Nanomedicine       Date:  2020-11-28       Impact factor: 5.307

Review 6.  A roadmap for neurodevelopmental disease modeling for non-stem cell biologists.

Authors:  Carl Ernst
Journal:  Stem Cells Transl Med       Date:  2020-02-13       Impact factor: 6.940

Review 7.  The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?

Authors:  Norman R Saunders; Mark D Habgood; Kjeld Møllgård; Katarzyna M Dziegielewska
Journal:  F1000Res       Date:  2016-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.